Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: Impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival

Bone Marrow Transplantation

Volumn 35, Issue 10, 2005, Pages 985-990

  Carlson, Kristina ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

High dose melphalan iohexol clearance; Multiple myeloma; OAS; Toxicity

Indexed keywords

ACICLOVIR; ALPHA2B INTERFERON; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IOHEXOL; MELPHALAN; NYSTATIN; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CELL ISOLATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HEMODIALYSIS; HUMAN; INCIDENCE; INFECTION; KIDNEY CLEARANCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYELOMA; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; GLOMERULAR FILTRATION RATE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IOHEXOL; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES;

EID: 19044363969     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704948     Document Type: Article

References (22)

1. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma, Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
2. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multi-center sequential randomized clinical trial. Blood 1998; 92: 3131-3136.
3. Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 2000; 95: 7-11.
4. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693-1695.
5. Knudsen LM, Hippe E, Hjorth M et al. Renal function in newly diagnosed multiple myeloma. Eur J Haematol 1994; 53: 207-212.
6. Iggo N, Palmer ABD, Severn A et al. Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment. Q J Med 1989; 270: 903-910.
7. Innes A, Cuthbert RJ, Russell NH et al. Intensive treatment of renal failure in patients with multiple myeloma. Clin Lab Haematol 1994; 16: 149-156.
8. Johnson WJ, Kyle RA, Pineda AA et al. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis and chemotherapy. Arch Intern Med 1990; 150: 863-869.
9. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Eur J Haematol 2000; 65: 175-181.
10. Torra R, Bladé J, Cases A, Lopez-Pedret J. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854-859.
11. Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822-829.
12. Ballester OF, Tummala R, Janssen WE et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 1997; 20: 653-656.
13. San Miguel JF, Lahuerta JJ, Garcia-Sanz R et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000; 1: 28-36.
14. 2 as a surrogate marker of outcome in patients with myeloma. Br J Cancer 2001; 85: 325-332.
15. Tosi P, Zamagni E, Ronconi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000; 14: 1310-1313.
16. Tricot G, Alberts DS, Johnson C et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996; 2: 947-952.
17. Lee C-K, Zangari M, Barlogie B et al. Myeloma. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823-828.
18. Child A, Morgan G, Davies F et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
19. Lenhoff S, Hjorth M, Westin J et al. Impact of age on survival after high-dose therapy with autologous stem cell support in newly diagnosed multiple myeloma: a population-based study. (submitted for publication).
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
21. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (Suppl. 1): S1-S266.
22. Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autolgous stem cell transplantation in multiple myeloma with renal failure. Blood 2003; 102: 985a (abstract 3667).